Land transport can no longer meet the requirements.European transport can be described by these words−crowded motorways and cities,dangerous emissions,ubiquitous traffic accidents,delays,expensive railways.Solutions a...Land transport can no longer meet the requirements.European transport can be described by these words−crowded motorways and cities,dangerous emissions,ubiquitous traffic accidents,delays,expensive railways.Solutions are being sought to transfer a large part of passengers and especially freight transport to(high-speed)rail,and efforts are moving towards electromobility,car-sharing,5G-connectivity,autonomous driving,MaaS(Mobility as a Service)-coordinated transport or hyperloop-type solutions.However,all these solutions have additional challenges and limitations.Solutions are not being searched where they really exist-in the mutual adaptation of road and rail vehicles and their deep cooperation.The ComplexTrans project shows that simply adapting the dimensions and functions of road and rail vehicles can eliminate(or at least significantly reduce)all the problems of existing land transport.The main features of the ComplexTrans system are sufficient parking spaces,reduction of urban and non-urban congestion,electric vehicles with unlimited range and cheaper than standard cars,cheaper and more accessible battery charging,“autonomous ride”,solving the overlap between passenger and freight rail transport and making it self-financing,transferring intercity freight transport to rail,replacing part of continental air transport and many others.The cost-effective and clustered individual transport and individualised public transport of the ComplexTrans system also bring very significant reductions in the risk of transmission of covid-19 and other contagious diseases during transport.展开更多
目的探究利多卡因体外下调ATP结合转运蛋白G家族成员2(ATP binding cassette transporter G family member 2,ABCG2)抑制人乳腺癌细胞的活性及顺铂耐药性的可能机制。方法选取MDA-MB-231、MCF-7细胞,使用CCK-8、EdU、TUNEL法染色验证利...目的探究利多卡因体外下调ATP结合转运蛋白G家族成员2(ATP binding cassette transporter G family member 2,ABCG2)抑制人乳腺癌细胞的活性及顺铂耐药性的可能机制。方法选取MDA-MB-231、MCF-7细胞,使用CCK-8、EdU、TUNEL法染色验证利多卡因对细胞增殖活性、顺铂干预增敏作用,RT-PCR和Western印迹法检测利多卡因对ABCG2以及凋亡蛋白、耐药蛋白表达及PI3K/Akt蛋白磷酸化的影响;CCK-8法、TUNEL法验证过表达ABCG2对利多卡因联合顺铂干预乳腺癌细胞系增殖活性、凋亡率。结果0.5 mmol/L干预时乳细胞存活率及EdU阳性细胞数显著降低(P<0.05);与对照组相比,利多卡因组和顺铂组细胞存活率、Bcl-2表达显著降低,细胞凋亡率、Cleaved-PARP、Cleaved-caspase-3、Bax表达量显著升高,联合处理后变化更显著(P<0.05);利多卡因处理后,癌细胞系中ABCG2 mRNA及蛋白表达水平降低(P<0.05);与对照组比较,顺铂+利多卡因组ABCG2、P-gp、MRP1、MRP2蛋白表达显著降低(P<0.05);与顺铂组比较,利多卡因组细胞存活率、p-PI3K/PI3K、p-AKT/AKT表达显著降低(P<0.05),细胞凋亡率显著升高(P<0.05);与空质粒组比较,ABCG2过表达组细胞存活率、p-PI3K/PI3K、p-AKT/AKT表达显著升高(P<0.05),细胞凋亡率显著降低(P<0.05)。结论利多卡因可能通过抑制ABCG2表达及PI3K/AKT信号通路的激活抑制乳腺癌细胞增殖活性及提高对顺铂敏感性。展开更多
目的研究miR-144-3p靶向调控ATP结合转运蛋白G家族成员2(ATP-binding transporter G family member 2,ABCG2)对胃癌(gastriccancer,GC)HGC-27细胞侵袭和迁移能力的影响,并对其作用机制进行初步探讨.方法通过qRT-PCR检测人GCHGC-27细胞...目的研究miR-144-3p靶向调控ATP结合转运蛋白G家族成员2(ATP-binding transporter G family member 2,ABCG2)对胃癌(gastriccancer,GC)HGC-27细胞侵袭和迁移能力的影响,并对其作用机制进行初步探讨.方法通过qRT-PCR检测人GCHGC-27细胞株和人胃黏膜上皮GES-1细胞株中miR-144-3p和ABCG2的表达情况;通过靶基因预测软件预测miR-144-3p和ABCG2靶向结合位点,通过双荧光素酶报告基因实验检测二者靶向结合关系;通过qRT-PCR检测miR-144-3p mimic或miR-144-3p inhibitor转染GC细胞后miR-144-3p及ABCG2的表达水平;通过明胶酶谱实验检测对转染ABCG2 siRNA的GC细胞中基质金属蛋白酶-2(matrix metalloproteinase-2, MMP-2)和基质金属蛋白酶-9(matrix metalloproteinase-9, MMP-9)活性的影响;通过Transwell侵袭和迁移实验检测转染miR-144-3p mimic、miR-144-3p inhibitor、ABCG2 siRNA对GC细胞侵袭和迁移能力的影响.结果与正常细胞组人胃黏膜上皮GES-1细胞株相比, GC细胞组人GCHGC-27细胞株中miR-144-3p的表达量明显降低, ABCG2的表达水平明显升高,差异具有统计学意义(P<0.05);靶基因预测miR-144-3p和ABCG2 3’UTR存在结合位点,双荧光素酶报告基因实验证实了miR-144-3p和ABCG2靶向结合关系;与对照组相比,转染miR-144-3p mimic组GC细胞中miR-144-3p的表达明显升高, ABCG2的表达明显降低,细胞侵袭和迁移能力显著降低,差异具有统计学意义(P<0.05),转染miR-144-3p inhibitor则表现出相反的作用;明胶酶谱实验检测结果表明ABCG2 siRNA转染可显著抑制GC细胞中MMP-2和MMP-9蛋白活性,抑制GC细胞侵袭和迁移能力,差异具有统计学意义(P<0.05).结论 MiR-144-3p能够抑制GC细胞侵袭和迁移能力,其作用机制与靶向调控ABCG2-MMP-2/9信号通路有关.展开更多
Background: More and more chronic kidney disease (CKD) patients are accompanied with hyperuricaemia. As is known, hyperuricaemia is an independent hazard of both cardiovascular diseases (CVD) and chronic kidney diseas...Background: More and more chronic kidney disease (CKD) patients are accompanied with hyperuricaemia. As is known, hyperuricaemia is an independent hazard of both cardiovascular diseases (CVD) and chronic kidney diseases. We aim at identifying Single Nucleotide Polymorphism (SNP) difference of hURAT1 (rs7932775) and ABCG2 (rs3825016) on CKD patient with hyperuricemia and/or gout. Methods: All forty-two CKD patients were divided into two groups: hyperuricemia, and control group. 24 hours urine sample and serum were prepared for testing biochemistry parameters. The polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method is used to analyze hURAT1 and ABCG2 single nucleotide polymorphisms in different groups. Results: 17 patients have CT SNP of hURAT1 (rs7932775) and 13 patients have CT SNP of ABCG2 (rs3825016) in hyperuricemia group, while only 5 persons and 6 persons have the same mutations in control group respectively. 7 patients have CT SNP of both hURAT1 (rs7932775) and ABCG2 (rs3825016) in hyperuricemia group, while only 2 persons have the same mutations in control group. CT mutation rates of hURAT1 (rs7932775) and ABCG2 (rs3825016) in hyperuricemia group were 60.7% (17/28) and 50% (13/28) respectively, higher than that of control group (35.7% (5/14) and 42.8% (6/14)). What is more, Double SNP mutations in both hURAT1 (rs7932775) and ABCG2 (rs3825016) in hyperuricemia group were 25% (7/28), higher than that of control group (14.2%, 2/14). Conclusion: There are higher mutation rates of CT SNP in hURAT1 (rs7932775) and/or ABCG2 (rs3825016) in hyperuricemia group. We can conclude that hyperuricemia is a high risk factor in progress of CKD, which is necessary to take measures of decreasing serum uric acid to delay CKD progress.展开更多
Colorectal cancer(CRC)ranks third in the number of cancers mainly because of the inability to diagnose it at an early stage.The pathogenesis of CRC is complicated,which is the result of the complex interaction of mult...Colorectal cancer(CRC)ranks third in the number of cancers mainly because of the inability to diagnose it at an early stage.The pathogenesis of CRC is complicated,which is the result of the complex interaction of multiple genetic and environmental factors.Currently,one of the main treatments for CRC is chemotherapy.But the primary cause of CRC treatment failure is drug resistance.The expression of cyclin-dependent kinase 9(CDK9)was correlated with elevated autophagy levels in colon cancer,and high expression of CDK9 indicates a poor prognosis in CRC.The incidence of autophagy and the expressions of Beclin 1 and ATP binding cassette transporter G2 are different in left and right colon cancer,and autophagy may be involved in the occurrence of chemotherapy resistance.In this article,the roles of CDK9,ATP binding cassette transporter G2 and Beclin 1 in CRC were elucidated,emphasizing the linkages among them and providing potential therapeutic targets of CRC.展开更多
基金This research is partly supported by project SGS-2019-001The 3-D visualisations were prepared by students of University of West Bohemia or by professional designers.
文摘Land transport can no longer meet the requirements.European transport can be described by these words−crowded motorways and cities,dangerous emissions,ubiquitous traffic accidents,delays,expensive railways.Solutions are being sought to transfer a large part of passengers and especially freight transport to(high-speed)rail,and efforts are moving towards electromobility,car-sharing,5G-connectivity,autonomous driving,MaaS(Mobility as a Service)-coordinated transport or hyperloop-type solutions.However,all these solutions have additional challenges and limitations.Solutions are not being searched where they really exist-in the mutual adaptation of road and rail vehicles and their deep cooperation.The ComplexTrans project shows that simply adapting the dimensions and functions of road and rail vehicles can eliminate(or at least significantly reduce)all the problems of existing land transport.The main features of the ComplexTrans system are sufficient parking spaces,reduction of urban and non-urban congestion,electric vehicles with unlimited range and cheaper than standard cars,cheaper and more accessible battery charging,“autonomous ride”,solving the overlap between passenger and freight rail transport and making it self-financing,transferring intercity freight transport to rail,replacing part of continental air transport and many others.The cost-effective and clustered individual transport and individualised public transport of the ComplexTrans system also bring very significant reductions in the risk of transmission of covid-19 and other contagious diseases during transport.
文摘目的探究利多卡因体外下调ATP结合转运蛋白G家族成员2(ATP binding cassette transporter G family member 2,ABCG2)抑制人乳腺癌细胞的活性及顺铂耐药性的可能机制。方法选取MDA-MB-231、MCF-7细胞,使用CCK-8、EdU、TUNEL法染色验证利多卡因对细胞增殖活性、顺铂干预增敏作用,RT-PCR和Western印迹法检测利多卡因对ABCG2以及凋亡蛋白、耐药蛋白表达及PI3K/Akt蛋白磷酸化的影响;CCK-8法、TUNEL法验证过表达ABCG2对利多卡因联合顺铂干预乳腺癌细胞系增殖活性、凋亡率。结果0.5 mmol/L干预时乳细胞存活率及EdU阳性细胞数显著降低(P<0.05);与对照组相比,利多卡因组和顺铂组细胞存活率、Bcl-2表达显著降低,细胞凋亡率、Cleaved-PARP、Cleaved-caspase-3、Bax表达量显著升高,联合处理后变化更显著(P<0.05);利多卡因处理后,癌细胞系中ABCG2 mRNA及蛋白表达水平降低(P<0.05);与对照组比较,顺铂+利多卡因组ABCG2、P-gp、MRP1、MRP2蛋白表达显著降低(P<0.05);与顺铂组比较,利多卡因组细胞存活率、p-PI3K/PI3K、p-AKT/AKT表达显著降低(P<0.05),细胞凋亡率显著升高(P<0.05);与空质粒组比较,ABCG2过表达组细胞存活率、p-PI3K/PI3K、p-AKT/AKT表达显著升高(P<0.05),细胞凋亡率显著降低(P<0.05)。结论利多卡因可能通过抑制ABCG2表达及PI3K/AKT信号通路的激活抑制乳腺癌细胞增殖活性及提高对顺铂敏感性。
文摘Background: More and more chronic kidney disease (CKD) patients are accompanied with hyperuricaemia. As is known, hyperuricaemia is an independent hazard of both cardiovascular diseases (CVD) and chronic kidney diseases. We aim at identifying Single Nucleotide Polymorphism (SNP) difference of hURAT1 (rs7932775) and ABCG2 (rs3825016) on CKD patient with hyperuricemia and/or gout. Methods: All forty-two CKD patients were divided into two groups: hyperuricemia, and control group. 24 hours urine sample and serum were prepared for testing biochemistry parameters. The polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method is used to analyze hURAT1 and ABCG2 single nucleotide polymorphisms in different groups. Results: 17 patients have CT SNP of hURAT1 (rs7932775) and 13 patients have CT SNP of ABCG2 (rs3825016) in hyperuricemia group, while only 5 persons and 6 persons have the same mutations in control group respectively. 7 patients have CT SNP of both hURAT1 (rs7932775) and ABCG2 (rs3825016) in hyperuricemia group, while only 2 persons have the same mutations in control group. CT mutation rates of hURAT1 (rs7932775) and ABCG2 (rs3825016) in hyperuricemia group were 60.7% (17/28) and 50% (13/28) respectively, higher than that of control group (35.7% (5/14) and 42.8% (6/14)). What is more, Double SNP mutations in both hURAT1 (rs7932775) and ABCG2 (rs3825016) in hyperuricemia group were 25% (7/28), higher than that of control group (14.2%, 2/14). Conclusion: There are higher mutation rates of CT SNP in hURAT1 (rs7932775) and/or ABCG2 (rs3825016) in hyperuricemia group. We can conclude that hyperuricemia is a high risk factor in progress of CKD, which is necessary to take measures of decreasing serum uric acid to delay CKD progress.
基金Supported by the National Natural Science Foundation of China,No.82272996the Science and Technology Program of Guangzhou,No.202206010081.
文摘Colorectal cancer(CRC)ranks third in the number of cancers mainly because of the inability to diagnose it at an early stage.The pathogenesis of CRC is complicated,which is the result of the complex interaction of multiple genetic and environmental factors.Currently,one of the main treatments for CRC is chemotherapy.But the primary cause of CRC treatment failure is drug resistance.The expression of cyclin-dependent kinase 9(CDK9)was correlated with elevated autophagy levels in colon cancer,and high expression of CDK9 indicates a poor prognosis in CRC.The incidence of autophagy and the expressions of Beclin 1 and ATP binding cassette transporter G2 are different in left and right colon cancer,and autophagy may be involved in the occurrence of chemotherapy resistance.In this article,the roles of CDK9,ATP binding cassette transporter G2 and Beclin 1 in CRC were elucidated,emphasizing the linkages among them and providing potential therapeutic targets of CRC.
